A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
A Randomized, Double-blind, Parallel Control, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of HLX04 and Bevacizumab Combined With Oxaliplatin and Fluoropyrimidine-based Chemotherapy (XELOX or mFOLFOX6) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Sponsor: Shanghai Henlius Biotech
A PHASE3 clinical study on Metastatic Colorectal Cancer (mCRC), this trial is completed. The trial is conducted by Shanghai Henlius Biotech and has accumulated 10 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE3
Status: Unknown → Completed
-
Sep 2024 — Feb 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jun 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2022 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Feb 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Jun 2020 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Henlius Biotech
For direct contact, visit the study record on ClinicalTrials.gov .